NO RESISTANCE TO TENOFOVIR ALAFENAMIDE ( TAF) IN ADULT, HBEAG- POSITIVE AND HBEAG- NEGATIVE PARTICIPANTS WITH CHRONIC HEPATITIS B INFECTION TREATED WITH TAF FOR UP TO 8 YEARS.

被引：0
|
作者：
Mateo, Roberto [1 ]
Chan, Henry Lik Yuen [2 ]
Marcellin, Patrick [3 ]
Pan, Calvin Pan [4 ]
Yazdi, Tahmineh [1 ]
Chang, Silvia [1 ]
Han, Dong [1 ]
May, Lindsey [1 ]
Marceau, Caleb [1 ]
Richards, Christopher [1 ]
Manhas, Savrina [1 ]
Ho, Pui Yan [1 ]
Li, Robert [1 ]
Xu, Simin [1 ]
Martinez, Clarissa [1 ]
Liu, Yang [1 ]
Peinovich, Nadine [1 ]
Lopez, Andrew [1 ]
Abramov, Frida [1 ]
Flaherty, John F. [1 ]
Mo, Hongmei [1 ]
Izumi, Namiki [5 ]
Buti, Maria [6 ,7 ]
Dr Shalimar [8 ]
Lim, Young-Suk [9 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[3] Beaujon Hosp, Clichy, France
[4] NYU, Grossman Sch Med, New York, NY USA
[5] Japanese Red Cross Musashino Hosp, Dept Gastroenterol & Hepatol, Musashino, Tokyo, Japan
[6] Hosp Univ Vall Dhebron, Barcelona, Spain
[7] Inst Carlos III, Ciberehd, Barcelona, Spain
[8] All India Inst Med Sci, New Delhi, India
[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1430-C
引用
收藏
页码：S532 / S533
页数：2
相关论文
共 50 条
  • [1] No detectable resistance to tenofovir disoproxil fumarate in HBeAg plus and HBeAg- patients with chronic hepatitis B after 8years of treatment
    Liu, Y.
    Corsa, A. C.
    Buti, M.
    Cathcart, A. L.
    Flaherty, J. F.
    Miller, M. D.
    Kitrinos, K. M.
    Marcellin, P.
    Gane, E. J.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (01) : 68 - 74
  • [2] Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B
    Chan, Henry Lik Yuen
    Lim, Young-Suk
    Seto, Wai Kay Walter
    Agarwal, Kosh
    Brunetto, Maurizia R.
    Janssen, Harry L. A.
    Caruntu, Florin
    Stepanova, Tatjana
    Tsang, Owen
    Yatsuhashi, Hiroshi
    Tak, Won Young
    Chen, Chi-Yi
    Celen, Mustafa
    Suri, Vithika
    Flaherty, John F.
    Lin, Lanjia
    Cathcart, Andrea
    Gaggar, Anuj
    Pan, Calvin Q.
    Shalimar
    Buti, Maria
    HEPATOLOGY, 2018, 68 : 227A - 228A
  • [3] NO DETECTABLE RESISTANCE TO TENOFOVIR DISOPROXIL FUMARATE (TDF) FOLLOWING UP TO 240 WEEKS OF TREATMENT IN PATIENTS WITH HBEAG plus AND HBEAG- CHRONIC HEPATITIS B VIRUS INFECTION
    Marcellin, Patrick
    Heathcote, E. Jenny
    Corsa, Amoreena
    Liu, Yang
    Miller, Michael D.
    Kitrinos, Kathryn M.
    HEPATOLOGY, 2011, 54 : 480A - 480A
  • [4] No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg plus and HBeAg- Patients with Chronic Hepatitis B (CHB) After Eight Years of Treatment
    Corsa, Amoreena C.
    Liu, Yang
    Flaherty, John F.
    Marcellin, Patrick
    Miller, Michael D.
    Kitrinos, Kathryn M.
    HEPATOLOGY, 2014, 60 : 1020A - 1020A
  • [5] Resistance surveillance of HBeAg- chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)
    Xiong, S
    Yang, H
    Westland, CE
    Delaney, WE
    Colledge, D
    Bartholomeusz, A
    Thibault, V
    Benhamou, Y
    Angus, P
    Wulfsohn, M
    Gibbs, CS
    Fry, J
    Brosgart, CL
    Locarnini, S
    JOURNAL OF HEPATOLOGY, 2003, 38 : 182 - 182
  • [6] CLINICAL PROGNOSIS OF HBEAG- NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B WITH LOW HBSAG
    Wang, Jian
    Zhu, Li
    Zhang, Zhiyi
    Yin, Shengxia
    Zhang, Shaoqiu
    Fan, Tao
    Xiong, Ye
    Jiang, Chao
    Liu, Xingxiang
    Li, Jie
    Zhu, Chuanwu
    Wu, Chao
    Huang, Rui
    HEPATOLOGY, 2024, 80 : S297 - S298
  • [7] OUTCOMES OF NUCLEOS( T) IDE ANALOG DISCONTINUATION IN HBEAG- POSITIVE CHRONIC HEPATITIS B PATIENTS WITHOUT ACHIEVING HBEAG LOSS
    Peng, Chien-Wei
    Liu, Yen-Chun
    Jeng, Rachel Wen-Juei
    Chien, Rong-Nan
    HEPATOLOGY, 2024, 80 : S277 - S277
  • [8] Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies
    Buti, Maria
    Agarwal, Kosh
    Chan, Henry Ly
    Seto, Wai-Kay
    Lim, Young-Suk
    Brunetto, Maurizia
    Chuang, Wan-Long
    Janssen, Harry
    Fung, Scott
    Izumi, Namiki
    Jablkowski, Maciej
    Abramov, Frida
    Wang, Hongyuan
    Yee, Leland
    Mateo, Roberto
    Flaherty, John F.
    Pan, Calvin
    Shalimar
    Marcellin, Patrick
    Gane, Edward J.
    JOURNAL OF HEPATOLOGY, 2023, 78 : S57 - S57
  • [9] Lack of emerging resistance mutations in 467 HBeAg- and HBeAg plus patients with chronic hepatitis B receiving adefovir dipivoxil for 48 weeks
    Yang, HL
    Westland, C
    Delaney, W
    Gibbs, C
    Miller, M
    Fry, J
    Brosgart, C
    Xiong, S
    JOURNAL OF HEPATOLOGY, 2002, 36 : 137 - 138
  • [10] Comparative antiviral efficacy with higher ALT normalization of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative, genotype D chronic hepatitis B
    Ricco, G.
    Buti, M.
    Omata, M.
    Kim, Y. J.
    Coco, B.
    Samuel, D.
    Flaherty, J. F.
    Lin, L.
    Gaggar, A.
    Ceausu, E.
    Akarca, U. S.
    Tong, M. J.
    Chan, H. L.
    Brunetto, M. R.
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (01) : E63 - E63
12345